# Luvo Health reviews (2026): GLP-1 telehealth sellers | This GLP

Everything is priced per four weeks and per week at once, with twelve, twenty-four and fifty-two week blocks published beside it.

Publisher: This GLP Editorial Team
Canonical: https://thisglp.com/reviews/luvo-health
Updated: 2026-10-28

Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Weekly rate, four blocks

# Luvo Health review

Everything is priced per four weeks and per week at once, with twelve, twenty-four and fifty-two week blocks published beside it.

## The verdict

Luvo Health publishes $249 per four weeks for compounded semaglutide by injection, and states the same figure as $62 a week alongside it. Three longer commitments are published in full: $657 for twelve weeks, $1,194 for twenty-four and $2,327 for fifty-two, each cutting the weekly rate a little further.

**Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures).

Category

GLP-1 telehealth

Molecule

Semaglutide · Tirzepatide

Form

Injection · Oral

Dose pricing

Flat across doses

Injection

From $271/mo

Oral

From $303/mo

Prescription

Required

Compounded

Yes — not FDA-approved

Luvo Health sells both molecules, with semaglutide available as an injection or an oral and tirzepatide by injection. Every line carries four figures — a four-week price and three block prices — which means a reader can see the entire commitment ladder on one screen rather than discovering it at checkout.

1.  ## Who writes the prescription, and what do they see?
    
    A prescription precedes dispensing and the pages concentrate on terms rather than on the clinician behind them. The intake is not documented, so what a prescriber reviews before writing is not something a reader can establish here — a gap that sits oddly beside pricing this thoroughly disclosed.
    
    The four-week interval is the thing to register before comparing anything. A year at Luvo is thirteen four-week periods rather than twelve months, and the fifty-two-week block price is where that becomes visible: $2,327 against what thirteen separate four-week charges at $249 would cost. Publishing the annual block is what lets a reader do that arithmetic at all.
    
2.  ## What happens when the dose goes up?
    
    Luvo states its rates hold at every dose. Combined with the published block prices, that makes a full-year calculation genuinely possible here. The two unknowns that usually defeat the exercise, [dose escalation](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and term pricing, are both addressed on the page.
    
3.  ## What the price includes
    
    The weekly framing is unusually honest here because Luvo gives both numbers rather than only the small one. Semaglutide runs $249 per four weeks or $62 a week; the oral is $279 and $70; tirzepatide is $339 and $85. Each longer block lowers the weekly rate, so the ladder rewards commitment in a visible, checkable way rather than an advertised one.
    
4.  ## What it claims, and what it cites
    
    Every line is compounded, which means none has been through the FDA review an approved product completes before dispensing. The oral [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) carries the highest four-week figure of the three lines, which runs against the usual pattern where a tablet undercuts an injection.
    

## Where it holds up, and where it does not

-   Strength: Four commitment lengths published on each line
-   Strength: Both the weekly and four-week figure given
-   Strength: Rate stated to hold at every dose
-   Strength: A full year can actually be calculated
-   Limitation: Four-week billing means thirteen periods
-   Limitation: The oral costs more than the injection
-   Limitation: No milligram dose is published
-   Limitation: No state coverage list is recorded

## What the evidence says about this kind of treatment

The assessment above is about Luvo Health. These are about the drugs it sells, and they are traced to the primary literature.

-   [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1)
-   [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1)
-   [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain)

Right for

A reader who wants to price a full year before starting and can read a four-week interval correctly.

Wrong for

A reader comparing against monthly sellers without adjusting for the shorter period.

## The evidence behind what Luvo Health prescribes

These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.

-   [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review)
    
    A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
    
-   [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better)
    
    In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
    

## How Luvo Health compares

| Seller | Who it suits | Go |
| --- | --- | --- |
| Pallas Health | A reader past the opening quarter who wants check-ins priced in, not billed per visit. |  |
| Trimi Health | A reader who can pay a year at once, or finance it, and wants the per-month figure to stop moving as the dose rises. |  |
| Lean Meds | Readers willing to clarify the prescription and renewal details |  |

[Compare all providers side by side →](https://thisglp.com/best)

More GLP-1 telehealth sellers reviews: [Nurx](https://thisglp.com/reviews/nurx) [Olleve Care](https://thisglp.com/reviews/ollevecare) [Omada Health](https://thisglp.com/reviews/omada-health) [One80Rx](https://thisglp.com/reviews/one80rx) [Pillar Health](https://thisglp.com/reviews/pillar-health) [Prescriva](https://thisglp.com/reviews/prescriva)

Sponsored alternative

SkinnyRx

Readers choosing tirzepatide, the one line with a published standing rate

## Frequently asked

Is $249 a monthly price?

No. It covers four weeks, so a year is thirteen such periods rather than twelve. Luvo publishes a fifty-two-week block at $2,327, which is the figure to compare against an annual total elsewhere.

Do the longer blocks actually save money?

Yes, and visibly: each block lowers the stated weekly rate, from $62 on the four-week price down across the twelve, twenty-four and fifty-two week commitments.

Why is the tablet more expensive?

That is how Luvo prices it, at $279 per four weeks against $249 for the injection. The pages offer no reason, and the direction runs against most of the category.

Is Luvo Health expensive compared with other GLP-1 telehealth sellers?

Luvo Health publishes a starting figure of $271/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Luvo Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.

Or [compare every seller we cover](https://thisglp.com/best).

**Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms).
